Kasny Recon Pharma Private Limited
This company manufactures, trades, and deals with pharmaceutical and cosmetic products, as well as conducts research and acts as an agent.
2006 | Mahesana, Gujarat (India) | Active
Kasny Recon Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 18 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 39.40%
- Ebitda 70.97%
- Net Worth -16.07%
- Total Assets -2.56%
About Kasny Recon Pharma
Kasny Recon Pharma Private Limited (KRPPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 September 2006 and has a history of 18 years and five months. Its registered office is in Mahesana, Gujarat, India.
The Corporate was formerly known as Recon Bio Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jahnavi Vaidya and Khyati Vaidya serve as directors at the Company.
Company Details
- Location
Mahesana, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24239GJ2006PTC049050
- Company No.
049050
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Sep 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Pharma
Who are the key members and board of directors at Kasny Recon Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jahnavi Vaidya  | Director | 30-Apr-2024 | Current |
| Khyati Vaidya | Director | 30-Apr-2024 | Current |
Financial Performance of Kasny Recon Pharma.
Kasny Recon Pharma Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 39.4% increase in profit. The company's net worth observed a substantial decline by a decrease of 16.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kasny Recon Pharma?
In 2019, Kasny Recon Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kasny Recon Pharma?
Unlock and access historical data on people associated with Kasny Recon Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kasny Recon Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kasny Recon Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
